ES2117717T3 - Tratamiento de tumores con factores neurotroficos e inhibidores de la proliferacion celular. - Google Patents

Tratamiento de tumores con factores neurotroficos e inhibidores de la proliferacion celular.

Info

Publication number
ES2117717T3
ES2117717T3 ES93920383T ES93920383T ES2117717T3 ES 2117717 T3 ES2117717 T3 ES 2117717T3 ES 93920383 T ES93920383 T ES 93920383T ES 93920383 T ES93920383 T ES 93920383T ES 2117717 T3 ES2117717 T3 ES 2117717T3
Authority
ES
Spain
Prior art keywords
cell proliferation
neuroblastoma cells
tumors
inhibitors
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93920383T
Other languages
English (en)
Inventor
Patrizia Lopresti
Wojciech Poluha
Dorota K Poluha
Alonzo H Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Worcester Foundation for Biomedical Research
Original Assignee
Worcester Foundation for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Worcester Foundation for Biomedical Research filed Critical Worcester Foundation for Biomedical Research
Application granted granted Critical
Publication of ES2117717T3 publication Critical patent/ES2117717T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCRIBEN METODOS Y COMPOSICIONES PARA EL TRATAMIENTO DE NEUROBLASTOMA. LOS METODOS INCLUYEN EL CONTACTO DE NEUROBLASTOMA CON UN FACTOR NEUROTROFICO Y MENOS DE UNA DOSIS LETAL DE UN INHIBIDOR DE PROLIFERACION CELULAR DURANTE UN PERIODO ENTRE 1 Y 15 DIAS, Y MANTENIENDO DESPUES EL NEUROBLASTOMA EN CONTACTO CON EL FACTOR NEUROTROFICO DURANTE UN TIEMPO ADICIONAL DE 1 A 15 DIAS. LA COMPOSICION INCLUYE UN FACTOR NEUTROFICO TAL COMO LA NEUROTROPINA, FACTOR DE DESARROLLO DE NERVIOS, Y UN INHIBIDOR DE PROLIFERACION CELULAR TAL COMO AFIDICOLINA, TIMIDINA O HIDROXIUREA. TAMBIEN SE DESCRIBEN METODOS PARA INDUCIR LA REMISION O DIFERENCIACION DE, O ELIMINACION DE, UN NEUROBLASTOMA.
ES93920383T 1992-08-27 1993-08-26 Tratamiento de tumores con factores neurotroficos e inhibidores de la proliferacion celular. Expired - Lifetime ES2117717T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/936,923 US5387520A (en) 1992-08-27 1992-08-27 Treatment of tumor cells in vitro with neurotrophic factors and cell proliferation inhibitors

Publications (1)

Publication Number Publication Date
ES2117717T3 true ES2117717T3 (es) 1998-08-16

Family

ID=25469222

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93920383T Expired - Lifetime ES2117717T3 (es) 1992-08-27 1993-08-26 Tratamiento de tumores con factores neurotroficos e inhibidores de la proliferacion celular.

Country Status (10)

Country Link
US (1) US5387520A (es)
EP (1) EP0658117B1 (es)
JP (1) JPH08500836A (es)
AT (1) ATE167630T1 (es)
CA (1) CA2141935A1 (es)
DE (1) DE69319346T2 (es)
DK (1) DK0658117T3 (es)
ES (1) ES2117717T3 (es)
GR (1) GR3027661T3 (es)
WO (1) WO1994005315A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789187A (en) * 1992-08-27 1998-08-04 Worcester Foundation For Experimental Biology Identification of differentiation factor receptors which inhibit the tumorigenicity of neuroblastoma cells in a ligand-independent manner
EP0632008B1 (en) * 1993-06-01 1998-02-04 Ono Pharmaceutical Co., Ltd. Pentanoic acid derivatives
JPH0856655A (ja) * 1994-08-16 1996-03-05 Frontier:Kk 細胞致死剤および細胞死抑制剤
US5648220A (en) * 1995-02-14 1997-07-15 New England Medical Center Hospitals, Inc. Methods for labeling intracytoplasmic molecules
WO2007105218A2 (en) * 2006-03-14 2007-09-20 Yeda Research And Development Co. Ltd. Composition and method for brain tumor therapy
CN114732839A (zh) * 2022-01-25 2022-07-12 长春中医药大学 人参总皂苷碳纳米点在制备抗神经母细胞瘤、抑制神经母细胞瘤细胞药物制剂领域中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE25661T1 (de) * 1982-11-10 1987-03-15 Ici Plc Aphidicolanderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
US5008252A (en) * 1987-03-20 1991-04-16 The University Of North Carolina At Chapel Hill Process for inhibiting herpes simplex virus-specified thymidine kinase

Also Published As

Publication number Publication date
DE69319346T2 (de) 1999-04-01
EP0658117A1 (en) 1995-06-21
CA2141935A1 (en) 1994-03-17
EP0658117B1 (en) 1998-06-24
US5387520A (en) 1995-02-07
DE69319346D1 (de) 1998-07-30
GR3027661T3 (en) 1998-11-30
JPH08500836A (ja) 1996-01-30
DK0658117T3 (da) 1999-02-01
ATE167630T1 (de) 1998-07-15
WO1994005315A1 (en) 1994-03-17

Similar Documents

Publication Publication Date Title
BR9710689A (pt) Processo para tratar diarr-ia aguda e para proporcionar terapia a um mam¡fero tendo diarr-ia e prepara-Æo terap-utica para redu-Æo de sintomas de diarr-ia
MX9707732A (es) Compuestos triciclicos utiles en el tratamiento de desordenes proliferativos de celulas.
TR199902194T2 (xx) +p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
UA74325C2 (uk) ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ р38, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇХ МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ ЗА ЇХ ДОПОМОГОЮ
EA199900464A1 (ru) Способы и композиции для стимуляции роста невритов
UA81398C2 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
FI953593A0 (fi) G-CSF-analogikoostumuksia ja menetelmiä
ATE63748T1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
MY121548A (en) Compounds and methods for the treatment of cancer
MY100641A (en) Neutral metalloendopeptidase inhibitors in the treatment of hypertension.
ES2196082T3 (es) Analagos del factor de crecimiento de queratinocitos.
SE8803071D0 (sv) Bakteriebehandling for att bevara hokvalitet genom att tillegga genius bacillus mikroorganismer
AU2209500A (en) Inhibitors of alpha4beta1 mediated cell adhesion
ES2117717T3 (es) Tratamiento de tumores con factores neurotroficos e inhibidores de la proliferacion celular.
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
GB9811279D0 (en) Keratinocyte growth factor-2 products
AU2427288A (en) Biological materials, processes for producing biological materials and for using such materials in therapy
DE69911629D1 (de) Zusammensetzungen und deren verwendung zur hemmung von angiogenese
WO1996016084A3 (en) A method of identifying cftr-binding compounds useful for activating chloride conductance in animal cells
AU578125B2 (en) Pyrazine diazohydroxide compounds
DK0925064T3 (da) 5-Androsten-3-beta,17-alpha-diol som inhibitor for tumorvækst
KR940702380A (ko) 종양 및 육종의 치료 방법(A Method for the treatment of Tumours and Sarcomas)
ES8502162A1 (es) Procedimiento para preparar un hidrolizado proteinico
Egorov et al. New Aspects of Biotechnology and Medicine
Jeon et al. The 100-kDa protein, whose phosphorylation precedes the fusion of chick embryonic myoblasts, is the eukaryotic elongation factor-2

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 658117

Country of ref document: ES